Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection

References

• Choo Q, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62
   PubMed Web of Science ®Google Scholar
• Hepatitis C, fact sheet No. 164, 2000. World Health Organization; Geneva: 2000
   Google Scholar
• Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infection in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm infect 2004;80:326-7
   PubMed Web of Science ®Google Scholar
• Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997;1(3):559-68
   PubMedGoogle Scholar
• Chen S, Morgan T. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
   PubMedGoogle Scholar
• Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009;83:7366-74
   PubMed Web of Science ®Google Scholar
• Cohn J, Piot P, Swan T, et al. UNITAID can address HCV/HIV co-infection. Lancet 2013;381(9867):628
   PubMedGoogle Scholar
• The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: a collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50(10):1387-96
   PubMed Web of Science ®Google Scholar
• Rosenthal EG, Pialoux N, Bernard C, et al. Liver related mortality in HIV infected patients between 1995-2003 in the French GERMIVIC joint study group network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-8
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomised trial. Lancet 2001;358(9286):958-65
   PubMed Web of Science ®Google Scholar
• Cunningham M, Foster G. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol 2012;5(2):139-51
   PubMedGoogle Scholar
• Sitole M, Silva M, Sponer L, et al. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. J Clin Ther 2013;35(2):190-7
   PubMed Web of Science ®Google Scholar
• British HIV Association. Management of hepatitis viruses in adults infected with HIV. HIV Med 2013;14(Suppl 4):1-s
   Google Scholar
• Alkhouri N. Protease inhibitors: Silver bullets for chronic hepatitis C infection? Cleve Clin J Med 2012;79(3):213-22
   PubMed Web of Science ®Google Scholar
• Levin J. Adherence with Telaprevir BID versus every 8 hour dosing in treatment-naïve HCV-infected patients: results from the Phase III OPTIMIZE study. Proceedings of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL);Amsterdam, The Netherlands; 2013
   Google Scholar
• Welsch C, Wang Y, Zettler M, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50(6):1709-18
   PubMedGoogle Scholar
• Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011;54(3):781-8
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson. Available from: www.jnj.com/news/all/OLYSIO-simeprevir-Receives-FDA-Approval-for-Combination-Treatment-of-Chronic-Hepatitis-C
   Google Scholar
• Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. abstract 1413 Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver; Amsterdam, The Netherlands; 2013
   Google Scholar
• Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) plus PEG-IFN/ribavirin in HCV genotype-1/HIV-1 coinfection (Study C212). abstract 24 Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
   Google Scholar
• UK medicines information. Available from: www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5112 [Last accessed 15 May 2014]
   Google Scholar
• Moreno C, Berg T, Tanwandee T, et al. A Phase IIa, Open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6. abstract 895 Program and abstracts of the 59th American Association of the Study of Liver Diseases (AASLD);San Francisco, CA, USA;2008
   Google Scholar
• Foster GR, Jacobson IM, Dore GJ, et al. Simeprevir (TMC435) with peginterferon/ribavirin for the treatment of chronic HCV genotype 1 infection in treatment-naïve European patients in the quest-1 and quest-2 phase III trials. abstract 1127 Program and abstracts of the 49th European Association for the Study of the Liver (EASL); London, UK; 2014
   Google Scholar
• Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138(3):913-21
   PubMed Web of Science ®Google Scholar
• Sherwat AI. Simeprevir medical review. food and drug administration center for drug evaluation and research. office of drug evaluation. Maryland, USA: 2013
   Google Scholar
• Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2013;49(1):138-47
   PubMedGoogle Scholar
• Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. abstract 1425 Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver; Amsterdam, The Netherlands; 2013
   Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase iii trial. Gastroenterology 2014;5085(14):293-5
   Google Scholar
• Rouan MC, Snoeys S, Ouwerkerk-Mahadevan R, et al. Combination therapy with simeprevir and TMC647055/low dose Ritonavir: dose anticipation using PBPK modeling and dose optimisation un healthy subjects. Proceedings of the 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Cambridge, MA, USA;2013
   Google Scholar
• Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. J Antivir Ther 2011;16(7):1021-33
   PubMed Web of Science ®Google Scholar
• Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012;56(6):1247-53
   PubMedGoogle Scholar
• Lenz O, Vijgen L, Moreno C, et al. Virologic response and characterisation of HCV genotypes 2-6 under TMC435 monotherapy. Proceedings of International Workshop on HIV and Hepatitis Drug Resistance and Curative Strategies; Los Cabos, Mexico; 2011
   Google Scholar
• Huisman M, Snoeys J, Monbaliu J, et al. TMC435 in combination with peginterferon and ribavirin in treatment naïve HCV genotype 1 patients. Final analysis of the PILLAR Phase IIb Study (TMC435-C205). Poster 278 presented at 61st Annual Meeting of the American Assosiation for the Study of Liver Diseases (AASLD); Boston, MA, USA; 2010
   Google Scholar
• Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58(6):1918-29
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Berg T, Gane E, et al. Tmc435 In HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final Svr24 results of the aspire trial. abstract 2 Program and abstracts of the 47th European association of the liver meeting; Barcelona, Spain;2012
   Google Scholar
• Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61(2):219-27
   PubMed Web of Science ®Google Scholar
• Reddy KR, Zeuzem S, Zoulim F, et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. (APASL) 24th Conference of the Asian Pacific Association for the Study of the Liver; 12-15 March 2014; Brisbane, Australia
   Google Scholar
• Ouwerkerk-Mahadevan S, Simion A, Mortier A, et al. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus. abstract 80 Program and Abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA, USA; 2012
   Google Scholar
• Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2). abstract 165 Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver; London, UK; 2014
   Google Scholar
• Zeuzem S, Hezode C, Bronowicki JP, et al. Daclatasvir in combination with simeprevir 
± ribavirin for hepatitis C virus genotype 1 infection. Abstract 28LB Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
   Google Scholar
• ClinicalTrials.gov. 3 year Follow-up Study in Patients Previously Treated With TMC435 for the Treatment of Hepatitis C (HCV) Infection. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01349465 [Last accessed 23rd May 2014]
   Google Scholar
• Riviere K. Biopharmaceutics review – simeprevir. Food and drug administration. USA. 2013. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf [Last accessed 12th May 2014]
   Google Scholar
• BHIVA Writing Group. British HIV association guidelines for the treatment of HIV positive adults with antiretroviral therapy 2013. HIV Med 2014;15(Supp 1):1-45
   Google Scholar
• Sulkowski M, Jacobson IM, Ghalib R, et al. Once daily simeprevir (TMC435) plus Sofosbuvir (GS-7977) with or without Ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS study subgroup analysis. abstract 07 Program and Abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver (EASL). London, England 2014
   Google Scholar
• Delaney M, Taylor J, Swan T, et al. Hepatitis C virus: from trials and tribulations to triumph. abstract 6 Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
   Google Scholar
• Ferenci P, Nyberg A, Bernstein D, et al. PEARL III: SVR ≥99% after 12 wks of ABT-450/r/267 + ABT-333 ± RBV in treatment naive HCV GT1b infection. abstract 29LB Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
   Google Scholar
• Ruane PJ, Ain D, Meshrekey R, et al. Sofosbuvir plus ribavirin, an interferon free regimen, in the treatment of treatment-naïve and treatment-experienced patients with chronic genotype 4 HCV infection. abstract 1243 Program and Abstracts of the 49th Annual Meeting of the European Association for the study of the liver (EASL); London, England; 2014
   Google Scholar